PATHOGENETIC METHOD OF TREATMENT OF GRANULOMATOUS ROSACEA

Background. Rosacea has recently acquired a torpid and atypical course. The treatment of patients with granulomatous subtype of rosacea has become not uncommon. The use of standard recommendations for antibiotic therapy, antiprotozoal, antimicrobial drugs, desensitizing therapy, systemic and topical isotretinoin does not give complete correction and stable results, which requires the study of other treatment methods. A method was developed and patented (Patent for Invention No. 2810402) for the pategenetic treatment of granulomatous subtype of rosacea. For 6 years (2018-2023), 200 patients with rosacea were under the supervision. The injection of 1% hyaluronic acid into the active zones and the application of 14% ferulic acid were effective. Purpose. To develop a treatment based on the 7 links of rosacea pathogenesis in the granulomatous subtype by injecting 1% hyaluronic acid into the active zones. Materials and methods. A sample of42 patients was taken to study and analyse the effect of hyaluronic acid on all links of pathogenesis in granulomatous subtype rosacea. The results of therapy were observed from 2018 to 2023 inclusive; 14 patients were male and 29 were female. The age of the patients ranged from 20 to 60 years. Results. The effect of 1% injectable hyaluronic acid on the course of rosacea was analyzed. We assessed the dynamics, the interval and the number of necessary procedures. The expected reactions after the treatment protocol were determined according to the Patent for Invention No. 2810402. A highly effective method of treating granulomatous subtype of rosacea was identified, taking into account the 7 links of pathogenesis with a long-term stable result, in which after the 4th procedure in 84% of cases positive dynamics were observed. 12 months later the result was enhanced and consolidated, which is confirmed by the clinical picture of the observed patients. Conclusion. After 6 procedures of pathogenetic treatment of granulomatous subtype of rosacea in 97.6% of cases the stagnation of the inflammatory process and cessation of clinical signs of the disease were observed.